Opportunities to replace fossile-based materials, more new products and services
Stora Enso said that it would maintain its capital expenditure (excluding investments to biological assets) at the level of depreciation. On the occasion of its Capital Markets Day held today in Helsinki, the company announced that in 2019, its estimated capital expenditure will be €550–600m, including €100m for biological assets. Its forecasted annual depreciation is €490–510m and operational decrease in the value of biological assets €50–70m. Capital expenditure amounts do not include potential acquisitions or divestments and are excluding the impact of IFRS 16 Leases, the company said.
Seeing many opportunities to replace fossil-based material, Stora Enso's long term target is to generate 15% of its sales with new products and services. Last year, the figure amounted to 7%.
This is an excerpt of our report on Stora Enso's market strategies presented at its Capital Markets Day. Find the full article in EUWID Pulp and Paper issue no 46/2018, which will be available to our e-paper and print subscribers.
Want to find out more? Check our subscriptions or test EUWID free of charge.